search
Back to results

Lentiviral Gene Therapy for MLD

Primary Purpose

Metachromatic Leukodystrophy (MLD)

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Lentivirus-mediated delivery of ARSA to the CNS.
Sponsored by
Shenzhen Geno-Immune Medical Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metachromatic Leukodystrophy (MLD) focused on measuring Metachromatic leukodystrophy (MLD), lentiviral vector

Eligibility Criteria

1 Month - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. MLD patient age >= 0 year
  2. ARSA gene sequence analysis to confirm MLD mutations
  3. Scoring system for brain MR Imaging confirmed MLD
  4. Parent / guardian / patient signing informed consent
  5. Patients and their families have a strong willingness to participate in clinical trials, and are willing to bear all the consequences caused by the failure of the trial, and sign an informed consent form

Exclusion Criteria:

  1. HIV positive patients
  2. Patients who are experiencing uncontrolled viral, bacterial or fungal infections, malignant tumors, heart abnormalities, liver dysfunction, or renal insufficiency
  3. Cannot perform an MRI
  4. Infection or dermatosis at pre-injection site
  5. Any condition that may increase the subjects' risk or interfere with the results of the trial. In addition to MLD, there are other neurological disorders.

Sites / Locations

  • Lung-Ji ChangRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lentivirus-mediated delivery of ARSA to the CNS.

Arm Description

Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene

Outcomes

Primary Outcome Measures

Safety of intracerebral injection of lentiviral TYF-ARSA.
Safety of intracerebral injection of lentiviral TYF-ARSA, determined by number of participants with treatment-related adverse events (AEs), according to scheduled assessments, vital signs, & physical examinations as assessed by CTCAE v4.0. AEs & clinically significant abnormalities (meeting grade 3, 4, or 5 criteria according to CTCAE) will be summarized by maximum intensity & relationship to study drug(s). Grade 1 & 2 AEs will be summarized if related to study therapy.
Altered disease progression
Altered disease progression based on biochemical analysis and MRI brain imaging analysis.

Secondary Outcome Measures

Full Information

First Posted
September 25, 2018
Last Updated
September 18, 2019
Sponsor
Shenzhen Geno-Immune Medical Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT03725670
Brief Title
Lentiviral Gene Therapy for MLD
Official Title
Gene Therapy for Metachromatic Leukodystrophy (MLD) Using a Self-inactivating Lentiviral Vector (TYF-ARSA)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
October 30, 2018 (Actual)
Primary Completion Date
October 30, 2018 (Actual)
Study Completion Date
November 1, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shenzhen Geno-Immune Medical Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase I/II clinical trial of gene transfer for treating Metachromatic leukodystrophy (MLD) using a safety and efficiency improved self-inactivating lentiviral vector TYF-ARSA to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
Detailed Description
Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disease. This disease is an inherited single gene autosomal recessive defect. MLD is caused by a mutation in the ARSA gene encoding arylsulfatase A which leads to a deficiency in sulfatide degradation, resulting in its accumulation in oligodendrocytes, Schwann cells and some neurons. A critical level of sulfatide storage can trigger demyelination, the hallmark of MLD, which results in multiple neurological symptoms. MLD has different onset ages including late infancy (1-2 years), adolescence (4 years-before sexual maturity) and adulthood (after sexual maturity). MLD patients are normally rescued by hematopoietic stem cell transplantation (HSCT) from a matched healthy donor. However, HSCT must be performed at a very early stage of the disease thus restricting its therapeutic opportunies in MLD patients. This trial aims to treat MLD using a safety and efficiency improved self-inactivating lentiviral vector carrying a functional MLD gene to correct the genetic defect by intracerebral injection to delivery the lentiviral vector carrying a normal ARSA gene to correct the pathogenic defect. The primary objectives are to evaluate the safety of the improved self-inactivating lentiviral vector TYF-ARSA, the in vivo gene transfer clinical protocol and the efficacy of degradative metabolite in patients at the time of treatment, assessment of vector integration sites, and finally the long-term correction of the related pathological symptoms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metachromatic Leukodystrophy (MLD)
Keywords
Metachromatic leukodystrophy (MLD), lentiviral vector

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lentivirus-mediated delivery of ARSA to the CNS.
Arm Type
Experimental
Arm Description
Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene
Intervention Type
Biological
Intervention Name(s)
Lentivirus-mediated delivery of ARSA to the CNS.
Intervention Description
Intracerebral LV gene therapy to deliver high level lenviral vectors which carry normal ARSA gene at 1-2×10^9 multiplicity of infection (moi)/ml per site.
Primary Outcome Measure Information:
Title
Safety of intracerebral injection of lentiviral TYF-ARSA.
Description
Safety of intracerebral injection of lentiviral TYF-ARSA, determined by number of participants with treatment-related adverse events (AEs), according to scheduled assessments, vital signs, & physical examinations as assessed by CTCAE v4.0. AEs & clinically significant abnormalities (meeting grade 3, 4, or 5 criteria according to CTCAE) will be summarized by maximum intensity & relationship to study drug(s). Grade 1 & 2 AEs will be summarized if related to study therapy.
Time Frame
up to 1 year follow up
Title
Altered disease progression
Description
Altered disease progression based on biochemical analysis and MRI brain imaging analysis.
Time Frame
up to 3 year follow up after treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: MLD patient age >= 0 year ARSA gene sequence analysis to confirm MLD mutations Scoring system for brain MR Imaging confirmed MLD Parent / guardian / patient signing informed consent Patients and their families have a strong willingness to participate in clinical trials, and are willing to bear all the consequences caused by the failure of the trial, and sign an informed consent form Exclusion Criteria: HIV positive patients Patients who are experiencing uncontrolled viral, bacterial or fungal infections, malignant tumors, heart abnormalities, liver dysfunction, or renal insufficiency Cannot perform an MRI Infection or dermatosis at pre-injection site Any condition that may increase the subjects' risk or interfere with the results of the trial. In addition to MLD, there are other neurological disorders.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lung-Ji Chang, Ph.D
Phone
86-0755-86725195
Email
c@szgimi.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lung-Ji Chang, Ph.D
Organizational Affiliation
Shenzhen Geno-Immune Medical Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lung-Ji Chang
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lung-Ji Chang, Ph.D
Phone
86-0755-86725195
Email
c@szgimi.org

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Lentiviral Gene Therapy for MLD

We'll reach out to this number within 24 hrs